TW202416967A - 用於治療第1型ifn介導疾病之s1p1受體調節劑 - Google Patents

用於治療第1型ifn介導疾病之s1p1受體調節劑 Download PDF

Info

Publication number
TW202416967A
TW202416967A TW112134792A TW112134792A TW202416967A TW 202416967 A TW202416967 A TW 202416967A TW 112134792 A TW112134792 A TW 112134792A TW 112134792 A TW112134792 A TW 112134792A TW 202416967 A TW202416967 A TW 202416967A
Authority
TW
Taiwan
Prior art keywords
type
ifn
treatment
interferon
modulators
Prior art date
Application number
TW112134792A
Other languages
English (en)
Inventor
丹尼爾 斯特拉瑟
馬克 莫非
Original Assignee
瑞士商愛杜西亞製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商愛杜西亞製藥有限公司 filed Critical 瑞士商愛杜西亞製藥有限公司
Publication of TW202416967A publication Critical patent/TW202416967A/zh

Links

Abstract

本發明係關於一種S1P <sub>1</sub>受體調節劑或其醫藥學上可接受之鹽，其用於預防或治療個體之第1型干擾素介導疾病，該個體具有高的第1型干擾素(IFN-1)基因標籤評分或該個體血漿中之干擾素-α (IFN-α)及/或干擾素-γ (IFN-γ)含量升高。
TW112134792A 2022-09-14 2023-09-13 用於治療第1型ifn介導疾病之s1p1受體調節劑 TW202416967A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63/375,668 2022-09-14

Publications (1)

Publication Number Publication Date
TW202416967A true TW202416967A (zh) 2024-05-01

Family

ID=

Similar Documents

Publication Publication Date Title
US10596173B2 (en) Combination therapy of an HBV capsid assembly inhibitor and an interferon
CA2253490C (en) Use of il-12 and ifn-.alpha. for the treatment of infectious diseases
SK124794A3 (en) Conventional leucocyte interferon, its use for production of treatment and pharmaceutical agent on its base
US20060258738A1 (en) Use of dronabinol for treatment of side effects of Hepatitis C therapy
KR20010052622A (ko) 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
WO2000066141A3 (en) Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
WO2005055955A3 (en) DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
TW202416967A (zh) 用於治療第1型ifn介導疾病之s1p1受體調節劑
WO2005087254A3 (en) Pharmaceutical compositions comprising interferon-tau
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
US8277793B2 (en) Prophylactic or therapeutic agent for viral disease
Ghosh et al. Physiological proteins in therapeutics: A current review on interferons
Koskinas et al. Granulocyte colony stimulating factor in HCV genotype‐1 patients who develop Peg‐IFN‐α2b related severe neutropenia: A preliminary report on treatment, safety and efficacy
WO1990004977A3 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
Zeuzem et al. TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised phase IIb trial
RU2212248C1 (ru) Способ лечения больных хроническим вирусным гепатитом c
EP1641485A1 (en) Inhibition of sars coronavirus infection with clinically approved antiviral drugs
CN103096885A (zh) 不饱和脂肪酸用于抑制病毒复制和/或感染的用途
WO2005058237A3 (en) Treatment of aids
Mita et al. Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan
JP2004529158A5 (zh)
KR20080027944A (ko) ＨＢＶ 치료용 ＰＥＧ-ＩＦＮ α 및 리바비린
WO2000051631A3 (en) Pegylated alpha interferon for hiv therapy